Production of a Highly Immunogenic Antigen from SARS-CoV-2 by Covalent Coupling of the Receptor Binding Domain of Spike Protein to a Multimeric Carrier

This article has been Reviewed by the following groups

Read the full article

Abstract

Since the discovery of SARS-CoV-2, several antigens have been proposed to be part of COVID-19 vaccines. The receptor binding domain (RBD) of Spike protein is one of the promising candidates to develop effective vaccines since it can induce potent neutralizing antibodies. We previously reported the production of RBD in Pichia pastoris and showed it is structurally identical to the protein produced in mammalian HEK-293T cells. In this work we designed an RBD multimer construct with the purpose of increasing RBD immunogenicity. We produced multimeric particles by a transpeptidation reaction between the RBD expressed in P. pastoris and Lumazine Synthase from Brucella abortus (BLS), which is a highly immunogenic and very stable decameric protein of 170 kDa. We vaccinated mice with two doses 30 days apart, and then we measured humoral immune response. When the number of RBD copies coupled to BLS was high (6-7 RBD molecules per BLS decamer, in average), the immune response was significantly better than that elicited by RBD alone or even by RBD-BLS comprising low number of RBD copies (1-2 RBD molecules per BLS decamer). Remarkably, the construct with high number of RBD copies induced high IgG titers with high neutralizing capacity. Furthermore, a superior immune response was observed when Al(OH)3 adjuvant was added to this formulation, exhibiting a higher titer of neutralizing antibodies. Altogether our results suggest that RBD covalent coupled to BLS forming a multimer-particle shows an advantageous architecture to the antigen-presentation to the immune system which enhances immune responses. This new antigen should be considered a potent candidate for a protein-based vaccine.

Article activity feed

  1. SciScore for 10.1101/2021.04.25.441271: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsIRB: Immunization Protocols: Mice immunization was carried out by experts from the High Level Technological Service from CONICET (STAN No. 4482), under guidelines from the Institutional Committee for the Care and Use of Laboratory Animals (CICUAL).
    Sex as a biological variableSix groups of five Females mice (6-8 week-old) (n=5) were immunized subcutaneously with the same amount of RBD protein (15 µg) coupled or not to BLS in the presence or absence of 500 µg aluminum hydroxide (Al(OH)3).
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Cell Line Authenticationnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    Half maximal inhibitory concentration (IC50), corresponding to the serum antibody dilution causing a 50% reduction of GFP positive cells compared to control “virus only” treated cells, was determined using the same software according to Ferrara and Temperton44.
    Temperton44
    suggested: None
    Experimental Models: Cell Lines
    SentencesResources
    Briefly, HEK-293T cells (2×107) were seeded in a 150-mm tissue culture dish in DMEM medium containing 10% FBS.
    HEK-293T
    suggested: None
    Experimental Models: Organisms/Strains
    SentencesResources
    BALB/c mice were obtained from the animal facility of the Faculty of Veterinary Sciences, University of La Plata (Argentina), and housed at the animal facility of the Instituto de Ciencia y Tecnología Dr. César Milstein, Fundación Pablo Cassará.
    BALB/c
    suggested: RRID:IMSR_ORNL:BALB/cRl)
    Recombinant DNA
    SentencesResources
    BLS Expression and Purification: A gene encoding a variant of lumazine synthase of Brucella abortus (BLS) including an N-terminal TEV site followed by a Gly-Gly-Gly sequence and a Gly-Ser-GLy-Ser-GLy spacer (Met-Glu-Asn-Leu-Tyr-Phe-Gln-Gly-Gly-Gly-Gly-Ser-GLy-Ser-Gly-BLS) was assembled and cloned in the pET11a vector (Novagen).
    pET11a
    suggested: RRID:Addgene_105501)
    ACE2 Expression and Purification: The expression plasmid pcDNA3-sACE2(WT)-8his, which includes the human ACE2 soluble domain (residues 1-615) coding gene, followed by a Gly-Ser-Gly linker and eight His residues for purification, was transfected in HEK-293T mammalian cells.
    pcDNA3-sACE2
    suggested: None
    ACE2 concentration was determined by UV spectrophotometry using an absorption coefficient of 157220 M−1 cm−1. TEV Protease Expression and Purification: Tobacco Etch Virus protease (TEV) was a gift from Helena Berglund (Addgene plasmid # 125194; http://n2t.net/addgene:125194; RRID:Addgene_125194)40.
    detected: RRID:Addgene_125194)
    Sortase A Expression and Purification: The Sortase A pentamutant (eSrtA) in pET29 was a gift from David Liu (Addgene plasmid # 75144; http://n2t.net/addgene:75144; RRID:Addgene_75144)41.
    pET29
    suggested: None
    detected: RRID:Addgene_75144)
    Addgene plasmid #11619; http://n2t.net/addgene:11619; RRID:Addgene_11619), a lentivirus backbone (VRC5602, NIH), and the Spike protein (VRC7475_2019-nCoV-S-WT, NIH).
    detected: RRID:Addgene_11619)
    The next day, cells were transfected with 10 μg of VRC5602, 5 μg pLB-GFP, and 3 μg of VRC7475_2019-nCoV-S-WT in OptiMEM medium using PEI in a 1:3 DNA:PEI ratio.
    pLB-GFP
    suggested: None
    Software and Algorithms
    SentencesResources
    Virus titers were calculated by counting the GFP positive cells using an automated counting tool in ImageJ (NIH), a titer of 200-225 GFP positive cells/field using 100X magnification was used for the assay.
    ImageJ
    suggested: (ImageJ, RRID:SCR_003070)
    Sera antibody neutralization titers were calculated by a nonlinear regression curve fit using GraphPad Prism software Inc. (La Jolla, CA).
    GraphPad Prism
    suggested: (GraphPad Prism, RRID:SCR_002798)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.


    Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


    Results from JetFighter: We did not find any issues relating to colormaps.


    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.


    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.